Janeková Andrea, Mojžiš Peter, Němcová Iveta, Kačerík Marek, Veselý Pavol, Hrčková Lucia
Eye Center Prague, Prague, Czech Republic.
Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
J Ophthalmol. 2025 Jul 24;2025:2662730. doi: 10.1155/joph/2662730. eCollection 2025.
To report the visual outcomes following bilateral implantation of a new trifocal intraocular lens (IOL) in patients with age-related cataracts. This prospective, noncomparative, multicenter study assessed 126 patients undergoing cataract extraction followed by AT ELANA 841P IOL implantation. At 4-6 months postoperatively, refractive error and predictability, monocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA), uncorrected near visual acuity (UNVA), distance-corrected near visual acuity (DCNVA), and binocular contrast sensitivity were measured. The binocular defocus curve was evaluated at 3 months postoperatively. Postoperatively, most of the eyes (84.9%) were within ±0.5 D of spherical equivalent (SE) refraction and almost all eyes (98.9%) within ±1.0 D, with a mean SE value of -0.11 ± 0.37 D. Mean monocular CDVA was -0.06 ± 0.08 logMAR and UDVA was -0.01 ± 0.10 logMAR. Mean monocular uncorrected (UIVA and UNVA) and distance-corrected visual acuities (DCIVA and DCNVA) were 0.1 logMAR or better at intermediate (80 cm) and near (40 cm) distances. In the mean defocus curve, a continuous range of 0.1 logMAR or better vision from distance to near was observed. Percentages of eyes achieving CDVA, DCIVA, and DCNVA of 0.1 logMAR or better were 97.2%, 59.1% and 59.1%, respectively. Uncorrected visual acuity of 0.1 logMAR or better was achieved in 88.9% of the eyes at far, 57.1% at intermediate, and 44.4% at near distances. Contrast sensitivity was in the normal range of a phakic population at all spatial frequencies in all light conditions tested, photopic with glare and mesopic with and without glare. Implantation of the new AT ELANA 841P IOL following cataract extraction is safe and effective. Visual acuities at all distances, refractive outcomes, and contrast sensitivity were favorable at 4-6 months postoperatively, providing patients with satisfactory far, intermediate, and near vision. ClinicalTrials.gov identifier: NCT06247683.
报告年龄相关性白内障患者双侧植入新型三焦点人工晶状体（IOL）后的视觉效果。这项前瞻性、非对照、多中心研究评估了126例接受白内障摘除术并随后植入AT ELANA 841P IOL的患者。术后4至6个月，测量屈光不正和可预测性、单眼未矫正远视力（UDVA）、矫正远视力（CDVA）、未矫正中视力（UIVA）、远距矫正中视力（DCIVA）、未矫正近视力（UNVA）、远距矫正近视力（DCNVA）以及双眼对比敏感度。术后3个月评估双眼散焦曲线。术后，大多数眼睛（84.9%）的等效球镜度（SE）屈光在±0.5D以内，几乎所有眼睛（98.9%）在±1.0D以内，平均SE值为-0.11±0.37D。平均单眼CDVA为-0.06±0.08 logMAR，UDVA为-0.01±0.10 logMAR。平均单眼未矫正（UIVA和UNVA）以及远距矫正视力（DCIVA和DCNVA）在中距离（80cm）和近距离（40cm）时为0.1 logMAR或更好。在平均散焦曲线中，观察到从远到近有连续范围的0.1 logMAR或更好的视力。达到CDVA、DCIVA和DCNVA为0.1 logMAR或更好的眼睛百分比分别为97.2%、59.1%和59.1%。在远距离、中距离和近距离，分别有88.9%、57.1%和44.4%的眼睛未矫正视力达到0.1 logMAR或更好。在所有测试光条件下（明视带眩光、暗视带和不带眩光）的所有空间频率下，对比敏感度均在有晶状体人群的正常范围内。白内障摘除术后植入新型AT ELANA 841P IOL是安全有效的。术后4至6个月时，所有距离的视力、屈光结果和对比敏感度均良好，为患者提供了满意的远、中、近视力。ClinicalTrials.gov标识符：NCT06247683。
